IL-37 (human) ELISA Kit
| Code | Size | Price |
|---|
| AG-45A-0041YEK-KI01 | 96 wells | £610.00 |
Quantity:
| AG-45A-0041YTP-KI01 | 2 x 96 wells | £1,000.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Target Species: Human
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Blue Ice
Storage:
4°C
Further Information
Alternate Names/Synonyms:
Interleukin-1 Family Member 7; IL-1F7; FIL1 zeta; IL-1X; Interleukin-1 Homolog 4; IL-1H4; Interleukin-1 zeta; IL-1 zeta; IL-1RP1; IL1F7; FIL1Z, IL1H4, IL1RP1
Assay Type:
Sandwich
Detection Type:
Colorimetric
EClass:
32160000
Handling Advice:
After standard reconstitution, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.Plate and reagents should reach room temperature before use.
Long Description:
ELISA Assay. Detects human IL-37. Does not cross-react with human IL-33, human IL-6, human IL-23, human IL-24 or mouse IL-33. Colorimetric assay. Sample Types: Plasma, Serum. Range: 0.016 to 1ng/ml. Sensitivity: 10pg/ml. IL-37 (IL-1F7; IL-1H4) is an IL-1 family member that is expressed only in certain types of human organs and cells such as heart, thymus, testis, kidney, mononuclear cells (PBMCs) and dendritic cells. IL-37 is an inhibitor of innate immunity with anti-inflammatory properties. It binds to the interleukin-18 receptor (IL-18R) and its co-receptor SIGIRR. IL-37 is secreted as a full-length and as a processed form starting from amino acid Val46. It plays an important role as a link between innate and adaptive immunity and acts as an inhibitor of autoimmune diseases and tumor growth. IL-37 also inhibited Lipopolysaccharide (LPS)-induced immunological reaction and LPS-induced osteoclast formation and bone resorption.
NCBI, Uniprot Number:
Q9NZH6
Package Type:
Box
Product Description:
IL-37 (IL-1F7; IL-1H4) is an IL-1 family member that is expressed only in certain types of human organs and cells such as heart, thymus, testis, kidney, mononuclear cells (PBMCs) and dendritic cells. IL-37 is an inhibitor of innate immunity with anti-inflammatory properties. It binds to the interleukin-18 receptor (IL-18R) and its co-receptor SIGIRR. IL-37 is secreted as a full-length and as a processed form starting from amino acid Val46. It plays an important role as a link between innate and adaptive immunity and acts as an inhibitor of autoimmune diseases and tumor growth. IL-37 also inhibited Lipopolysaccharide (LPS)-induced immunological reaction and LPS-induced osteoclast formation and bone resorption. A recent study indicates that IL-37 protein forms a head-to-head homodimer and this structure limits its bioactivity. Variants with mutations converting the cytokine into a monomeric form are 13 fold more active than the dimeric IL-37.
Range:
0.016 to 1ng/ml
Sample Type:
Plasma, Serum
Sensitivity:
10pg/ml
Specificity:
Detects human IL-37 (monomeric and dimeric forms). Does not cross-react with human IL-33, IL-38, IL-6, IL-23, IL-24 or mouse IL-33 and IL-38.
Transportation:
Non-hazardous
UNSPSC Number:
41116126
Use & Stability:
12 months after the day
References
Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment: C. Li, et al.; J. Interferon Cytokine Res. 33, 612 (2013) | Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with guillain-barr? syndrome: C. Li, et al.; Mediators Inflamm. 2013, 639712 (2013) | IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity: L. Ye, et al.; J. Transl. Med. 12, 69 (2014) | Plasma Levels of IL-37 and Correlation with TNF-alpha, IL-17A, and Disease Activity during DMARD Treatment of Rheumatoid Arthritis: P.-W. Zhao, et al.; PLOS One 9, e95346 (2014) | Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis: P. Italiani, et al.; J. Neuroinflamm. 11, 94 (2014) | Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome: Q. Ji, et al.; Mediat. Inflamm. 2014, ID165742 (2014) | Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity: B. Chen, et al.; J. Transl. Med. 13, 36 (2015) | The Evaluation of Plasma and Leukocytic IL-37 Expression in Early Inflammation in Patients with Acute ST-Segment Elevation Myocardial Infarction after PCI: X. Wang, et al.; Med. Inflamm. 2015, 626934 (2015) | Plasma Interleukin-37 Is Elevated in Patients with Rheumatoid Arthritis: Its Correlation with Disease Activity and Th1/Th2/Th17-Related Cytokines: T. Xia, et al. Dis. Markers 2015, 795043 (2015) | Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer: G. Ge, et al.; J. Exp. Clin. Cancer Res. 35, 13 (2016) | Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus: J. Godsell, et al.; Sci. Reports 6, 34604 (2016) | Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients: J. Huo, et al.; Arch. Gynecol. Obstet. 295, 459 (2017) | Interleukin-37 elevation in patients with atrial fibrillation: W. Li, et al.; Clin. Cardiol. 40, 66 (2017) | Homodimerization attenuates the anti-inflammatory activity of interleukin-37: A.M. Ellisdon, et al.; Sci. Immunol. 2, eaaj1548 (2017) | Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification: M. Chai, et al.; J. Geriatr. Cardiol. 14, 285 (2017) | Interleukin-37 mediates the antitumor activity in colon cancer through beta-catenin suppression: X. Yan, et al.; Oncotarget 8, 49064 (2017) | IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction: K. Liu, et al.; Clin. Chim. Acta 468, 140 (2017) | Plasma IL-37 Elevated in Patients with Chronic Heart Failure and Predicted Major Adverse Cardiac Events: A 1-Year Follow-Up Study: X. Shou, et al.; Dis. Markers 9134079 (2017) | Measurement of Elevated IL-37 Levels in Acute Ischemic Brain Injury: A Cross-sectional Pilot Study. A. Zafar, et al. Cureus 9, e1767 (2017) | Transgenic Overexpression of IL-37 Protects Against Atherosclerosis and Strengthens Plaque Stability: J. Liu, et al.; Cell. Physiol. Biochem. 45, 1034 (2018) | Interleukin-37 is increased in adult-onset Still?s disease and associated with disease activity: H. Chi, et al.; Arthr. Res. Ther. 20, 54 (2018) | Plasma interleukin-37 is increased and inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells in systemic juvenile idiopathic arthritis patients: M. Feng, et al.; J. Transl. Med. 16, 277 (2018) | IL-37 Attenuates Lung Fibrosis by Inducing Autophagy and Regulating TGF-b1 Production in Mice: M.S. Kim, et al.; J. Immunol. 203, 2265 (2019) | IL-37 increases in patients after ischemic stroke and protects from inflammatory brain injury, motor impairment and lung infection in mice: S.R. Zhang, et al.; Sci. Rep. 9, 6922 (2019) | Interleukin-37 sensitize the elderly type 2 diabetic patients to insulin therapy through suppressing the gut microbiota dysbiosis: T. Li, et al.; Mol. Immunol. 112, 322 (2019) | Plasma levels and expression of interleukin?37 in patients with immune thrombocytopenia: F. Zhang, et al.; Exp. Therap. Med. 18, 2739 (2019) | Short?term interleukin?37 treatment improves vascular endothelial function, endurance exercise capacity, and whole?body glucose metabolism in old mice: D.C. Ballak, et al.; Aging Cell 19, e13074 (2020) | Correlation Between Level of Interleukin-37 and Rheumatoid Arthritis Progression: J. Zhu, et al.; Int. J. Gen. Med. 14, 1905 (2021) | Circulating Interleukin-37 Levels in Healthy Adult Humans ? Establishing a Reference Range: D.M. Santarelli, et al.; Front. Immunol. 12, 708425 (2021) | Protein engineering of a stable and potent anti-inflammatory IL-37-Fc fusion with enhanced therapeutic potential: A. Bujotzek, et al.; Cell Chem. Biol. 29, 2451 (2022)
Related Products
| Product Name | Product Code | Supplier | IL-37 (truncated) (human) (rec.) (His) | AG-40A-0190 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|